Examining immune cell responses to teclistamab in multiple myeloma patients
Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination
NA · University Hospital, Toulouse · NCT05945524
This study is testing how different immune cells in multiple myeloma patients respond to the treatment teclistamab to see why some people benefit from it while others do not.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse (other) |
| Drugs / interventions | Teclistamab |
| Locations | 18 sites (Amiens, France and 17 other locations) |
| Trial ID | NCT05945524 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze the immune and oncogenomic characteristics that differentiate patients with multiple myeloma who respond to teclistamab from those who exhibit resistance. By focusing on single immune cell examination, the research will investigate both phenotypic and genotypic traits associated with primary and secondary resistance to the treatment. Bone marrow samples will be collected from participants to facilitate this analysis. The findings could provide insights into personalized treatment strategies for multiple myeloma.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with multiple myeloma who are receiving teclistamab and can provide informed consent.
Not a fit: Patients under legal protection may not benefit from this study due to exclusion criteria.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for multiple myeloma patients by identifying those most likely to benefit from teclistamab.
How similar studies have performed: While this approach is innovative, similar studies focusing on immune responses in cancer treatments have shown promise in identifying patient-specific treatment responses.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * With multiple myeloma * Who receive Teclistamab * Consent form signed Exclusion Criteria: * Patient under legal protection
Where this trial is running
Amiens, France and 17 other locations
- CHU d'Amiens — Amiens, France, France (RECRUITING)
- CHU de Caen — Caen, France, France (RECRUITING)
- Polyclinique du Parc Drevon — Dijon, France, France (RECRUITING)
- CH Annecy Genevois — Epagny Metz- Tessy, France, France (RECRUITING)
- CHU de Lille — Lille, France, France (RECRUITING)
- Centre Léon Bérard — Lyon, France, France (RECRUITING)
- CHU de Montpellier — Montpellier, France, France (RECRUITING)
- Hôpital Saint-Louis — Paris, France, France (RECRUITING)
- Hôpital Saint-Antoine — Paris, France, France (RECRUITING)
- Hôpital Necker — Paris, France, France (RECRUITING)
- CHU de Bordeaux — Pessac, France, France (RECRUITING)
- CHU de Lyon — Pierre-Bénite, France, France (RECRUITING)
- CHU de Poitiers — Poitiers, France, France (RECRUITING)
- CHU de Rennes — Rennes, France, France (RECRUITING)
- CH Saint-Etienne — Saint-Priest-en-Jarez, France, France (RECRUITING)
- CHU de Toulouse — Toulouse, France, France (RECRUITING)
- CHU de Tours — Tours, France, France (RECRUITING)
- CHRU Nancy — Vandœuvre-lès-Nancy, France, France (RECRUITING)
Study contacts
- Principal investigator: Hervé AVET LOISEAU, MD, PhD — University Hospital, Toulouse
- Study coordinator: Hervé AVET LOISEAU, MD, PhD
- Email: avetloiseau.herve@iuct-oncopole.fr
- Phone: +33 531 156 142
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Myeloma, Teclistamab, Resistance, Immune Cell